Cargando…

Inflammation and remodeling pathways and risk of cardiovascular events in patients with ischemic heart failure and reduced ejection fraction

Patients with heart failure (HF) and coronary artery disease (CAD) have a high risk for cardiovascular (CV) events including HF hospitalization, stroke, myocardial infarction (MI) and sudden cardiac death (SCD). The present study evaluated associations of proteomic biomarkers with CV outcome in pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Girerd, Nicolas, Cleland, John, Anker, Stefan D., Byra, William, Lam, Carolyn S. P., Lapolice, David, Mehra, Mandeep R., van Veldhuisen, Dirk J., Bresso, Emmanuel, Lamiral, Zohra, Greenberg, Barry, Zannad, Faiez
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123183/
https://www.ncbi.nlm.nih.gov/pubmed/35595781
http://dx.doi.org/10.1038/s41598-022-12385-0
_version_ 1784711499629985792
author Girerd, Nicolas
Cleland, John
Anker, Stefan D.
Byra, William
Lam, Carolyn S. P.
Lapolice, David
Mehra, Mandeep R.
van Veldhuisen, Dirk J.
Bresso, Emmanuel
Lamiral, Zohra
Greenberg, Barry
Zannad, Faiez
author_facet Girerd, Nicolas
Cleland, John
Anker, Stefan D.
Byra, William
Lam, Carolyn S. P.
Lapolice, David
Mehra, Mandeep R.
van Veldhuisen, Dirk J.
Bresso, Emmanuel
Lamiral, Zohra
Greenberg, Barry
Zannad, Faiez
author_sort Girerd, Nicolas
collection PubMed
description Patients with heart failure (HF) and coronary artery disease (CAD) have a high risk for cardiovascular (CV) events including HF hospitalization, stroke, myocardial infarction (MI) and sudden cardiac death (SCD). The present study evaluated associations of proteomic biomarkers with CV outcome in patients with CAD and HF with reduced ejection fraction (HFrEF), shortly after a worsening HF episode. We performed a case–control study within the COMMANDER HF international, double-blind, randomized placebo-controlled trial investigating the effects of the factor-Xa inhibitor rivaroxaban. Patients with the following first clinical events: HF hospitalization, SCD and the composite of MI or stroke were matched with corresponding controls for age, sex and study drug. Plasma concentrations of 276 proteins with known associations with CV and cardiometabolic mechanisms were analyzed. Results were corrected for multiple testing using false discovery rate (FDR). In 485 cases and 455 controls, 49 proteins were significantly associated with clinical events of which seven had an adjusted FDR < 0.001 (NT-proBNP, BNP, T-cell immunoglobulin and mucin domain containing 4 (TIMD4), fibroblast growth factor 23 (FGF-23), growth differentiation factor-15 (GDF-15), pulmonary surfactant-associated protein D (PSP-D) and Spondin-1 (SPON1)). No significant interactions were identified between the type of clinical event (MI/stroke, SCD or HFH) and specific biomarkers (all interaction FDR > 0.20). When adding the biomarkers significantly associated with the above outcome to a clinical model (including NT-proBNP), the C-index increase was 0.057 (0.033–0.082), p < 0.0001 and the net reclassification index was 54.9 (42.5 to 67.3), p < 0.0001. In patients with HFrEF and CAD following HF hospitalization, we found that NT-proBNP, BNP, TIMD4, FGF-23, GDF-15, PSP-D and SPON1, biomarkers broadly associated with inflammation and remodeling mechanistic pathways, were strong but indiscriminate predictors of a variety of individual CV events.
format Online
Article
Text
id pubmed-9123183
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-91231832022-05-22 Inflammation and remodeling pathways and risk of cardiovascular events in patients with ischemic heart failure and reduced ejection fraction Girerd, Nicolas Cleland, John Anker, Stefan D. Byra, William Lam, Carolyn S. P. Lapolice, David Mehra, Mandeep R. van Veldhuisen, Dirk J. Bresso, Emmanuel Lamiral, Zohra Greenberg, Barry Zannad, Faiez Sci Rep Article Patients with heart failure (HF) and coronary artery disease (CAD) have a high risk for cardiovascular (CV) events including HF hospitalization, stroke, myocardial infarction (MI) and sudden cardiac death (SCD). The present study evaluated associations of proteomic biomarkers with CV outcome in patients with CAD and HF with reduced ejection fraction (HFrEF), shortly after a worsening HF episode. We performed a case–control study within the COMMANDER HF international, double-blind, randomized placebo-controlled trial investigating the effects of the factor-Xa inhibitor rivaroxaban. Patients with the following first clinical events: HF hospitalization, SCD and the composite of MI or stroke were matched with corresponding controls for age, sex and study drug. Plasma concentrations of 276 proteins with known associations with CV and cardiometabolic mechanisms were analyzed. Results were corrected for multiple testing using false discovery rate (FDR). In 485 cases and 455 controls, 49 proteins were significantly associated with clinical events of which seven had an adjusted FDR < 0.001 (NT-proBNP, BNP, T-cell immunoglobulin and mucin domain containing 4 (TIMD4), fibroblast growth factor 23 (FGF-23), growth differentiation factor-15 (GDF-15), pulmonary surfactant-associated protein D (PSP-D) and Spondin-1 (SPON1)). No significant interactions were identified between the type of clinical event (MI/stroke, SCD or HFH) and specific biomarkers (all interaction FDR > 0.20). When adding the biomarkers significantly associated with the above outcome to a clinical model (including NT-proBNP), the C-index increase was 0.057 (0.033–0.082), p < 0.0001 and the net reclassification index was 54.9 (42.5 to 67.3), p < 0.0001. In patients with HFrEF and CAD following HF hospitalization, we found that NT-proBNP, BNP, TIMD4, FGF-23, GDF-15, PSP-D and SPON1, biomarkers broadly associated with inflammation and remodeling mechanistic pathways, were strong but indiscriminate predictors of a variety of individual CV events. Nature Publishing Group UK 2022-05-20 /pmc/articles/PMC9123183/ /pubmed/35595781 http://dx.doi.org/10.1038/s41598-022-12385-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Girerd, Nicolas
Cleland, John
Anker, Stefan D.
Byra, William
Lam, Carolyn S. P.
Lapolice, David
Mehra, Mandeep R.
van Veldhuisen, Dirk J.
Bresso, Emmanuel
Lamiral, Zohra
Greenberg, Barry
Zannad, Faiez
Inflammation and remodeling pathways and risk of cardiovascular events in patients with ischemic heart failure and reduced ejection fraction
title Inflammation and remodeling pathways and risk of cardiovascular events in patients with ischemic heart failure and reduced ejection fraction
title_full Inflammation and remodeling pathways and risk of cardiovascular events in patients with ischemic heart failure and reduced ejection fraction
title_fullStr Inflammation and remodeling pathways and risk of cardiovascular events in patients with ischemic heart failure and reduced ejection fraction
title_full_unstemmed Inflammation and remodeling pathways and risk of cardiovascular events in patients with ischemic heart failure and reduced ejection fraction
title_short Inflammation and remodeling pathways and risk of cardiovascular events in patients with ischemic heart failure and reduced ejection fraction
title_sort inflammation and remodeling pathways and risk of cardiovascular events in patients with ischemic heart failure and reduced ejection fraction
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123183/
https://www.ncbi.nlm.nih.gov/pubmed/35595781
http://dx.doi.org/10.1038/s41598-022-12385-0
work_keys_str_mv AT girerdnicolas inflammationandremodelingpathwaysandriskofcardiovasculareventsinpatientswithischemicheartfailureandreducedejectionfraction
AT clelandjohn inflammationandremodelingpathwaysandriskofcardiovasculareventsinpatientswithischemicheartfailureandreducedejectionfraction
AT ankerstefand inflammationandremodelingpathwaysandriskofcardiovasculareventsinpatientswithischemicheartfailureandreducedejectionfraction
AT byrawilliam inflammationandremodelingpathwaysandriskofcardiovasculareventsinpatientswithischemicheartfailureandreducedejectionfraction
AT lamcarolynsp inflammationandremodelingpathwaysandriskofcardiovasculareventsinpatientswithischemicheartfailureandreducedejectionfraction
AT lapolicedavid inflammationandremodelingpathwaysandriskofcardiovasculareventsinpatientswithischemicheartfailureandreducedejectionfraction
AT mehramandeepr inflammationandremodelingpathwaysandriskofcardiovasculareventsinpatientswithischemicheartfailureandreducedejectionfraction
AT vanveldhuisendirkj inflammationandremodelingpathwaysandriskofcardiovasculareventsinpatientswithischemicheartfailureandreducedejectionfraction
AT bressoemmanuel inflammationandremodelingpathwaysandriskofcardiovasculareventsinpatientswithischemicheartfailureandreducedejectionfraction
AT lamiralzohra inflammationandremodelingpathwaysandriskofcardiovasculareventsinpatientswithischemicheartfailureandreducedejectionfraction
AT greenbergbarry inflammationandremodelingpathwaysandriskofcardiovasculareventsinpatientswithischemicheartfailureandreducedejectionfraction
AT zannadfaiez inflammationandremodelingpathwaysandriskofcardiovasculareventsinpatientswithischemicheartfailureandreducedejectionfraction